Drugs / ADAPT6-SPECT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05412446 | May → Dec 2022 | breast cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADAPT6-SPECT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05412446 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes” NCT05412446 ↗ |